Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights UnitedHealth Group, Salesforce, Linde, IDEXX and Telefonica

Read MoreHide Full Article

For Immediate Release

Chicago, IL – March 30, 2023 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. (UNH - Free Report) , Salesforce, Inc. (CRM - Free Report) , Linde plc (LIN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Telefónica, S.A. (TEF - Free Report) .

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for UnitedHealth, Salesforce and Linde

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Salesforce, Inc. and Linde plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of UnitedHealth Group have underperformed the Zacks Medical - HMOs industry over the past year (-10.0% vs. -8.6%). The company’s membership in its global business continues to decline. Rising operating costs are hurting margins. As such, the stock warrants a cautious stance.

Nevertheless, UnitedHealth Group’s top line remains well-poised for growth on the back of a strong market position, new deals, renewed agreements, and expansion of service offerings. Its solid health services segment provides diversification benefits.

UNH's Government business remains well-poised for growth. A sturdy balance sheet enables business investments.

(You can read the full research report on United Health Group here >>>)

Shares of Salesforce have outperformed the Zacks Computer - Software industry over the past six months (+35.6% vs. +22.4%). The company is benefiting from a robust demand environment as customers are undergoing a major digital transformation. The rapid adoption of its cloud-based solutions is driving demand for its products.

Its sustained focus on introducing more aligned products as per customer needs is driving its top-line. Continued deal wins in the international market is another growth driver. The acquisition of Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft’s Teams product.

However, stiff competition and unfavorable currency fluctuations are concerns. Besides, challenging macroeconomic environment might hurt its growth prospects in the near-term.

(You can read the full research report on Salesforce here >>>)

Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+7.5% vs. -8.8%). With a wide range of applications for its industrial gases, Linde is making the world more productive by the day. The company’s primary products in industrial gases include oxygen, which is used as life support in hospitals. Its process gas, like hydrogen, is being utilized for clean fuels, while its high-purity and specialty gases are employed to manufacture electronics.

Linde has long-term contracts with on-site customers backed by minimum purchase requirements, thereby securing stable cashflows. In the profitable industrial gas market, the merger of Praxair and Linde has created an efficient player with considerable size advantages.

However, the cost of sales continues to increase, hurting the firm’s bottom line. The firm has mostly been paying a lower dividend yield than the industry’s composite stocks over the past two years.

(You can read the full research report on Linde here >>>)

Other noteworthy reports we are featuring today include IDEXX Laboratories, Inc. and Telefónica, S.A.

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in